Prevention of Preterm Labour: 2011 Update on Tocolysis

The aim of this paper is to review available data about drugs for preventing preterm labour. Tocolytic therapy includes β adrenergic receptor agonists, NO donors, magnesium sulphate, prostaglandin-synthase inhibitors, oxytocin receptor antagonists, calcium-channel blockers, progesterone, 17-α-hydrox...

Descripción completa

Detalles Bibliográficos
Autores principales: Hubinont, C., Debieve, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228310/
https://www.ncbi.nlm.nih.gov/pubmed/22175022
http://dx.doi.org/10.1155/2011/941057
_version_ 1782217810460540928
author Hubinont, C.
Debieve, F.
author_facet Hubinont, C.
Debieve, F.
author_sort Hubinont, C.
collection PubMed
description The aim of this paper is to review available data about drugs for preventing preterm labour. Tocolytic therapy includes β adrenergic receptor agonists, NO donors, magnesium sulphate, prostaglandin-synthase inhibitors, oxytocin receptor antagonists, calcium-channel blockers, progesterone, 17-α-hydroxyprogesterone caproate, and antibiotics. Their specific effects on myometrial contractility, their safety, their efficiency, and side effects profile for the mother and the fetus are presented. The main question of why and for what reasons tocolysis should be administrated is discussed.
format Online
Article
Text
id pubmed-3228310
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32283102011-12-15 Prevention of Preterm Labour: 2011 Update on Tocolysis Hubinont, C. Debieve, F. J Pregnancy Review Article The aim of this paper is to review available data about drugs for preventing preterm labour. Tocolytic therapy includes β adrenergic receptor agonists, NO donors, magnesium sulphate, prostaglandin-synthase inhibitors, oxytocin receptor antagonists, calcium-channel blockers, progesterone, 17-α-hydroxyprogesterone caproate, and antibiotics. Their specific effects on myometrial contractility, their safety, their efficiency, and side effects profile for the mother and the fetus are presented. The main question of why and for what reasons tocolysis should be administrated is discussed. Hindawi Publishing Corporation 2011 2011-11-15 /pmc/articles/PMC3228310/ /pubmed/22175022 http://dx.doi.org/10.1155/2011/941057 Text en Copyright © 2011 C. Hubinont and F. Debieve. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hubinont, C.
Debieve, F.
Prevention of Preterm Labour: 2011 Update on Tocolysis
title Prevention of Preterm Labour: 2011 Update on Tocolysis
title_full Prevention of Preterm Labour: 2011 Update on Tocolysis
title_fullStr Prevention of Preterm Labour: 2011 Update on Tocolysis
title_full_unstemmed Prevention of Preterm Labour: 2011 Update on Tocolysis
title_short Prevention of Preterm Labour: 2011 Update on Tocolysis
title_sort prevention of preterm labour: 2011 update on tocolysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228310/
https://www.ncbi.nlm.nih.gov/pubmed/22175022
http://dx.doi.org/10.1155/2011/941057
work_keys_str_mv AT hubinontc preventionofpretermlabour2011updateontocolysis
AT debievef preventionofpretermlabour2011updateontocolysis

Ejemplares similares